These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19454842)

  • 1. Black and white: rapamycin as a regulator of cardiac mTOR signaling.
    Madamanchi N; Patterson C
    Cell Cycle; 2009 Jun; 8(11):1646. PubMed ID: 19454842
    [No Abstract]   [Full Text] [Related]  

  • 2. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
    Wacheck V
    Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
    [No Abstract]   [Full Text] [Related]  

  • 3. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility.
    Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?
    Kwiatkowski DJ; Wagle N
    EBioMedicine; 2015 Jan; 2(1):2-4. PubMed ID: 26137524
    [No Abstract]   [Full Text] [Related]  

  • 6. Will mTOR inhibitors make it as cancer drugs?
    Sawyers CL
    Cancer Cell; 2003 Nov; 4(5):343-8. PubMed ID: 14667501
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic targets: MTOR and related pathways.
    Dancey JE
    Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raptor and mTOR: subunits of a nutrient-sensitive complex.
    Kim DH; Sabatini DM
    Curr Top Microbiol Immunol; 2004; 279():259-70. PubMed ID: 14560962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin: master regulator of cell growth in the nervous system.
    Sandsmark DK; Pelletier C; Weber JD; Gutmann DH
    Histol Histopathol; 2007 Aug; 22(8):895-903. PubMed ID: 17503347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option.
    Ringshausen I; Peschel C; Decker T
    Leuk Lymphoma; 2005 Jan; 46(1):11-9. PubMed ID: 15621776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new clue to explain resistance to mTOR inhibitors.
    Huang S
    Cell Cycle; 2012 Mar; 11(5):844. PubMed ID: 22336918
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
    Janus A; Linke A; Cebula B; Robak T; Smolewski P
    Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTOR pathway in breast cancer.
    Hynes NE; Boulay A
    J Mammary Gland Biol Neoplasia; 2006 Jan; 11(1):53-61. PubMed ID: 16900391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.
    Vollenbröker B; George B; Wolfgart M; Saleem MA; Pavenstädt H; Weide T
    Am J Physiol Renal Physiol; 2009 Feb; 296(2):F418-26. PubMed ID: 19019920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
    Papadimitrakopoulou V; Adjei AA
    J Thorac Oncol; 2006 Sep; 1(7):749-51. PubMed ID: 17409953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.
    Choo AY; Blenis J
    Cell Cycle; 2009 Feb; 8(4):567-72. PubMed ID: 19197153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.
    Rao RD; Buckner JC; Sarkaria JN
    Curr Cancer Drug Targets; 2004 Dec; 4(8):621-35. PubMed ID: 15578919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.